SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Eikon Therapeutics Reports $86.1 Million Q3 Net Loss, $461.7 Million in Cash

Eikon Therapeutics reported a third-quarter 2026 net loss attributable to common stockholders of $86.1 million, compared with $71.1 million a year earlier. The company ended September with $461.7 million in cash, cash equivalents and marketable securities, and expects its funds to support operation…

EIKN

Related stories